Coagulation factors bound by platelet-derived microvesicles

Coagulation factors bound by platelet-derived microvesicles (PMPs) represent a highly procoagulant assembly of proteins localized on the surface of small vesicles (0.1 to 1.0 μm) released from activated or apoptotic platelets (Burnier et al., 2009). These microvesicles provide a concentrated source of anionic phospholipids, primarily phosphatidylserine, which serves as a critical scaffold for the assembly of the tenase and prothrombinase complexes (Sinauridze et al., 2007). PMPs are known to carry and localize essential factors such as Factor Va, Factor VIII, and Factor IX, making them significantly more potent in thrombin generation than the surface of activated platelets alone (Nomura et al., 2008). In pathological states, elevated levels of these PMP-bound factors are associated with an increased risk of arterial and venous thrombosis, particularly in patients with cardiovascular disease, malignancy, or systemic inflammation (Del Conde et al., 2005). While current anticoagulant therapies like Factor Xa inhibitors and direct thrombin inhibitors effectively neutralize the activity of these factors, they do not specifically target the PMP-binding mechanism. Research into therapies that specifically inhibit PMP formation or their procoagulant surface interactions is ongoing to potentially provide more targeted antithrombotic effects with reduced bleeding risks (Tripodi, 2013).

Other names

Platelet microparticlesPMPsPlatelet-derived microparticlesProcoagulant platelet microvesiclesPlatelet-derived extracellular vesicles

Inhibition of the enzymatic activity of coagulation factors (e.g., Factor Xa, Thrombin) that are localized on the surface of platelet-derived microvesicles.